Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5252W HIGH $1,537.32
Volume
7.33 K
Value Traded
177.71 K
Short % Float
2.29%
Days to Cover
1.0
-7.55%Week
-46.23%1 Month
-70.8%3 Month
-89.84%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.08 M
EPS (TTM)
-16.66
P/E Ratio
-
Ent. Value
-16.71 M
Total Shares
809.58 K
Float Shares
810.00 K
Insiders
0.00%
Institutions
3.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ELAB Catalyst Timeline
Dated clinical, regulatory and corporate events for PMGC Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for PMGC Holdings Inc.
57Total events
2Upcoming
19Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 48
●Composition Patent FiledEL-22IP / Competition
Filed new U.S. patent application covering EL-22 formulations and dosing
muscle-wasting conditions (GLP-1-associated muscle loss, sarcopenia, muscle disuse atrophy, certain neurological disorders)source ↗
▲Partnership / LicenseCorporate
NorthStrive Defense Tech secures exclusive option to license U.S. Patent No. 12,277,716 B2 for GPS-denied autonomous drone navigation technology
▲Manufacturing MilestoneEL-32CMC / Inspection
Initiation of manufacturing optimization program for EL-32
muscle preservation in patients on GLP-1 receptor agonist weight loss therapysource ↗
▲Partnership / LicenseCorporate
AGA Precision Systems signs second long-term supply agreement with Tier 1 aerospace and defense company
▼Equity OfferingCorporate
Fully utilized $20M equity purchase facility with Streeterville Capital
●Composition Patent FiledEL-22IP / Competition
Filed 5 U.S. patent applications for EL-22 covering livestock, aquaculture, and poultry
muscle growth and yield enhancement in farmed animalssource ↗
●Composition Patent FiledEL-32IP / Competition
Filed 5 U.S. patent applications for EL-32 covering livestock, aquaculture, and poultry
muscle growth and yield enhancement in farmed animalssource ↗
▲Partnership / LicenseEL-22Corporate
Exclusive license agreement signed with Modulant Biosciences for EL-22 and EL-32 in animal health
muscle preservation in animal healthsource ↗
▲Partnership / LicenseEL-32Corporate
Exclusive license agreement signed with Modulant Biosciences for EL-22 and EL-32 in animal health
muscle preservation in animal healthsource ↗
◆Timing GuidancePresentation
Phase III expected to take approximately 6 to 9 weeks
obesity and related metabolic conditionssource ↗
●Trial InitiationTrial
Initiation of Phase III of AI Development Program with Yuva Biosciences
obesity and related metabolic conditionssource ↗
◆AcquisitionCorporate
AGA Precision Systems LLC completes acquisition of Indarg Engineering, Inc.
◆AcquisitionCorporate
Signing of non-binding LOI to acquire U.S.-based electronics manufacturing company
▲Partnership / LicenseEL-22Corporate
Northstrive signs binding term sheet with Modulant for exclusive global animal health licensing of EL-22
animal health (livestock and companion animals)source ↗
●Composition Patent FiledEL-22IP / Competition
Filed US patent application for EL-22 combination therapy with GLP-1 receptor agonist
muscle loss in obese patientssource ↗
●Composition Patent FiledEL-32IP / Competition
Filed US patent application for EL-32 combination therapy with GLP-1 receptor agonist
muscle loss due to obesity treatmentssource ↗
▲FDA Feedback ReceivedEL-22FDA Meeting
FDA preliminary responses supporting IND submission for Phase 2 trial of EL-22 in combination with GLP-1 receptor agonist
obesitysource ↗
▲Partnership / LicenseCorporate
Northstrive Biosciences enters into Development and License Agreement with Yuva Biosciences for AI-powered mitochondrial therapies
obesity, type 2 diabetes, cardiometabolic conditionssource ↗
▼Equity OfferingCorporate
Registered direct offering of 294,450 shares at $5.04 per share for gross proceeds of $1.48 million
◆Partnership / LicenseEL-22Corporate
Parties intend to finalize and execute definitive license agreement in coming months
animal health (livestock and companion animals)source ↗
●Trial InitiationEL-22Trial
Initiate U.S. clinical trials for EL-22 in combination with GLP-1
obesity with muscle loss preventionsource ↗
●Trial InitiationEL-32Trial
Initiate U.S. clinical trials for EL-32 in combination with GLP-1
obesity with muscle loss preventionsource ↗
◆Reverse Stock SplitCorporate
1-for-200 reverse stock split to maintain Nasdaq listing compliance
▲Preclinical PoCPreclinical
Efficacy study of new drug candidate for sarcopenia shows positive grip strength and rota-rod latency results
sarcopeniasource ↗
▲Trial CompletionTrial
Completion of clinical study of Elevai Enfinity topical exosome serum
facial photoagingsource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement with MOA Life Plus for EL-22 and EL-32
obesity and muscle loss preventionsource ↗
▲Partnership / LicenseCorporate
ELEVAI Labs acquires exclusive worldwide license for INmune Bio's EMx stem cell manufacturing technology
▲Partnership / LicenseCorporate
Elevai Labs enters licensing agreement with Yuva Biosciences to combine exosome and mitochondrial technologies for aesthetics products
aesthetics (skin and hair aging)source ↗
Past FDA Catalysts and PDUFA Decisions
How ELAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ELAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Elevai Enfinity Topical Exosome Serum | facial appearance improvement | 2024-08-26 | significant improvement noted across many aspects of skin appearanceRead More | Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome SerumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kovalyov GeorgeDirector | Grant/Award | 75,046 75,046 held | $0.00 | 06/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ELAB for Q2 2026. | ||||
ELAB Institutional Ownership Trends
ELAB Short Interest
Shares sold short, counted twice a month.
2.29%
Short % of Float
of tradable shares sold short
18.5K
Shares Sold Short
-32.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
31.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELAB ranks across every disease it competes in
Competitive Position is a premium feature
See how ELAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELAB News
ELABFinancial Statements of A&B AEROSPACE, INC. For the three and nine months ended
A&B Aerospace, Inc. has reported positive financial results for the three and nine months ended February 28, 2026, with substantial increases in net income compared to the prior year. For the three-month period, the company achieved a net income of $123,492, a significant turnaround from a loss in the prior year, while for the nine months, net income was $343,903. Operational cash flows also showed improvement, indicating robust financial health and the ability to cover operational needs. Total assets grew markedly, helping to bolster the company's balance sheet.
Read more →ELABUPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
NorthStrive Biosciences has filed a new U.S. patent application for EL-22, a myostatin-engineered probiotic aimed at treating muscle-wasting conditions. The application covers formulations and dosing regimens for patients affected by GLP-1 receptor agonist therapy, sarcopenia, and other muscle loss issues. This move is part of the company's strategy to strengthen its intellectual property portfolio.
Read more →ELABNorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
NorthStrive Biosciences has filed a new U.S. patent application for EL-22, a myostatin-engineered probiotic technology aimed at muscle preservation in humans. This application seeks to protect a pharmaceutical product intended for patients with muscle loss linked to conditions like sarcopenia and neurological disorders. The development is part of NorthStrive's broader strategy to build its intellectual property portfolio and offers potential therapeutic solutions that address increasing concerns about muscle health.
Read more →ELAB▼ -5.5%on this news· ran to -20% by day 1shared move
NorthStrive Defense Tech Acquires Patented GPS-Denied Autonomous Drone Navigation Technology Option, Built for Defense and Counter-Unmanned Aircraft Systems
NorthStrive Defense Tech LLC, a subsidiary of PMGC Holdings Inc., announced it has acquired an option for patented autonomous drone navigation technology designed for GPS-denied environments. This technology could enhance drone operations in defense and counter-drone applications. The acquisition marks the second contract for the company, potentially expanding its market portfolio. However, NorthStrive cannot guarantee the successful negotiation of a definitive license agreement for full commercialization.
Read more →ELABSVM Machining, Inc. Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products Co., Inc.
SVM Machining, Inc. has entered into a Long-Term Agreement with Turbo-Jet Products Co., Inc. to supply essential aerospace and defense components. This marks the third such agreement for PMGC Holdings' subsidiary in 2026. The five-year agreement enables SVM to support various defense programs while adhering to necessary federal regulations. Furthermore, the company is working towards AS9100 certification to bolster its manufacturing capabilities in regulated markets.
Read more →ELAB▼ -13.9%on this newsshared move
PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing
PMGC Holdings, Inc. has secured a $40 million equity purchase facility to accelerate its M&A strategy focused on aerospace and defense manufacturing. The company has already completed four acquisitions and aims to expand its precision manufacturing platform by leveraging favorable market dynamics. The capital will enable PMGC to pursue additional acquisitions and enhance its manufacturing capabilities to meet growing demand in these sectors. The company also looks to invest in automation and advanced manufacturing technologies while remaining open to opportunities outside its core areas.
Read more →ELAB▲ +6.1%on this news· ran to -20% by day 3
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences
NorthStrive Biosciences has announced the successful transfer of its EL-32 Working Cell Bank to a U.S. fermentation facility, marking a significant step in manufacturing optimization. This initiative aims to enhance production yield and support clinical development for its dual-action probiotic therapeutic targeting muscle preservation. The collaboration with Modulant Biosciences will facilitate process development for both human and animal health applications.
Read more →ELAB▲ +16.9%on this newsshared move
AGA Precision Systems Signs Second Long-Term Supply Agreement to Manufacture Aerospace and Defense Components for a Tier 1 Firm
AGA Precision Systems LLC announced a second long-term supply agreement with a Tier 1 aerospace and defense firm, formalizing a multi-year supplier-customer relationship. This agreement reflects AGA's ongoing commitment to quality and reliability in the defense supply chain. The arrangement includes commitments on quality, delivery, and pricing, appropriate for mission-critical applications. AGA aims to reinforce its reputation in the aerospace and defense sector as it continues to grow its operational visibility and recurring revenue potential.
Read more →ELAB▲ +30.4%on this news· ran to +52% by day 1shared move
PMGC Holdings Inc. [NASDAQ: ELAB] PMGC Holdings Fully Utilizes All
PMGC Holdings Inc. has announced the full utilization of a $20 million equity financing facility to strengthen its cash position and advance its acquisition strategy. With this funding, the company has completed acquisitions in precision CNC manufacturing and IT packaging sectors, enhancing its operational scale. Looking forward, PMGC plans to pursue both organic growth and additional acquisitions to maximize shareholder value and deepen its market presence. The management is committed to investing in assets that can generate sustainable cash flow.
Read more →ELAB▼ -32.9%on this newsshared move
NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications
NorthStrive Defense Tech, a subsidiary of PMGC Holdings Inc., has acquired rights to a novel drone technology designed to transport payloads across air and water. This advancement aims to enhance defense capabilities by enabling multi-domain operations. The company plans to negotiate a definitive license agreement for further commercialization, though success in these negotiations or the technology's development is not assured.
Read more →ELAB▼ -59.1%on this news· ran to -73% by day 1shared move
PMGC Holdings Inc. Announces the Formation of New Subsidiary, NorthStrive Defense Tech to Target High-Growth Defense, Drone and Autonomous Systems Sector
PMGC Holdings Inc. has announced the formation of a new subsidiary, NorthStrive Defense Tech, aimed at targeting the high-growth sectors of defense technology, particularly focusing on drones and autonomous systems. This initiative reflects PMGC's strategy to capitalize on the increasing global defense spending and the demand for innovative defense technologies. However, the company acknowledges the inherent uncertainties and risks associated with the future success of this venture, noting that there are no guarantees of revenue generation from the new subsidiary's activities.
Read more →ELAB▲ +68.3%on this news· ran to +293% by day 1shared move
Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products
AGA Precision Systems has signed a long-term agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components. This contract establishes a framework for future purchases and emphasizes AGA's role in serving U.S. government contracts. The agreement is backed by AGA's recent AS9100 certification and ITAR compliance, which underscores its commitment to quality and regulatory standards in the aerospace sector.
Read more →ELAB▼ -22.5%on this news· ran to -55% by day 3
SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts
SVM Machining, Inc., a subsidiary of PMGC Holdings, has announced the successful completion of its International Traffic in Arms Regulations (ITAR) registration. This achievement enables SVM to pursue contracts within the U.S. defense and aerospace sectors, complying with necessary export-control standards. The company believes the registration strengthens its status as a qualified supplier for Tier 1 defense contractors and supports its strategy for expansion into high-value manufacturing areas. The announcement highlights SVM's commitment to delivering high-quality precision machining services across various critical industries.
Read more →ELABPMGC Holdings Inc. Announces Anticipated Reverse Stock Split
PMGC Holdings Inc. announced a 1-for-6 reverse stock split effective at 12:00 am on March 10, 2026. Following this split, the company expects to have approximately 541,461 shares of common stock outstanding. This action is part of the company's broader strategy to potentially enhance its stock value, although reverse splits can sometimes be perceived negatively by investors. The company has advised investors to be cautious, as future performance is subject to numerous uncertainties.
Read more →ELABBiosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed
NorthStrive Biosciences has filed ten new patent applications for its technologies, EL-22 and EL-32, aimed at enhancing muscle growth and yield in various farmed animals, including livestock, poultry, and aquatic species. The applications not only focus on boosting muscle weight return but also on the potential to reduce harmful emissions associated with livestock farming. This innovative approach could position NorthStrive favorably within the animal health and agricultural markets. The company emphasizes the implications of its technologies for sustainability and efficiency in food production.
Read more →ELABNorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health
NorthStrive Biosciences has executed a definitive license agreement with Modulant Biosciences for the commercialization of its EL-22 and EL-32 myostatin-engineered probiotics. The agreement grants Modulant exclusive rights to develop and market these products specifically for non-human animal health applications. While this represents a significant step in advancing animal health technologies, the success of commercialization and regulatory approvals remains uncertain, highlighting the inherent risks of the industry.
Read more →ELAB▼ -40%on this news
PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.
PMGC Holdings Inc. has completed the acquisition of SVM Machining, Inc., a California-based ISO 9001:2015 Certified precision machining firm. This marks PMGC's third CNC machine shop acquisition in California, aligning with its strategy to strengthen its multi-site machining platform. SVM specializes in high-quality, engineered components for critical industries, including medical and aerospace. The acquisition aims to enhance PMGC's footprint in precision manufacturing.
Read more →ELAB▼ -12.7%on this news
PMGC Holdings Inc. Announces Reverse Stock Split Effective January 6, 2026
PMGC Holdings Inc. has announced a 1-for-4 reverse stock split effective January 6, 2026. Currently, the company has approximately 2,014,852 shares issued and outstanding, which will reduce to approximately 503,713 shares after the split. The announcement follows a prior disclosure on January 2, 2026, and includes a caution about the inherent uncertainties and risks associated with forward-looking statements. Investors are encouraged to consider the implications of the reverse stock split on their holdings.
Read more →ELAB▼ -29.7%on this news
NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries
NorthStrive Biosciences has announced the initiation of Phase III of its AI Development Program in partnership with Yuva Biosciences. This phase will focus on validating potential drug compounds identified in Phase II, aimed at treating obesity and preserving muscle health. The new phase will involve generating meaningful biological data over approximately six to nine weeks, utilizing YuvaBio's AI platform, MitoNova. The developments signify a critical step towards enhancing their therapeutic pipeline for metabolic conditions.
Read more →ELABPMGC Holdings Inc. Announces AGA Precision Systems LLC's ITAR (International Traffic in Arms Regulations) Registration Approval
PMGC Holdings Inc. has announced that its subsidiary, AGA Precision Systems LLC, has completed the ITAR registration process. This achievement positions AGA to engage in defense and aerospace programs that require compliance with U.S. export regulations. The ITAR registration improves AGA's status as a supplier for Tier 1 defense contractors and enhances PMGC's strategic goals for growth in the defense sector.
Read more →About PMGC Holdings Inc.
Headquarters120 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
BIOPHARMAWATCH ELITE PLUS
Trade the next ELAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime